Publication
What M&A trends will transform the 2024 insurance landscape?
It is widely accepted that 2023 was one of the worst years in recent memory for M&A activity.
Publication | November 2020
COVID-19 has put a significant focus on the pharmaceutical industry in the development of treatments and a vaccine. Because the pharmaceutical business is a global industry, legal frameworks vary from region to region, especially in the area of intellectual property. The Pharmaceutical Intellectual Property and Competition Law Review examines the complexities of the industry in multiple jurisdictions providing a useful tool for managing global risks.
Norton Rose Fulbright Canada contributed to this publication, providing an overview of the intellectual property laws in Canada and how they interact with Canada’s competition law.
Publication
It is widely accepted that 2023 was one of the worst years in recent memory for M&A activity.
Publication
The ongoing conflicts and further geopolitical tensions in Eastern Europe and the Middle East, coupled with upcoming elections in a number of key countries including the US and the UK, make 2024 challenging to predict what impact this will have on the insurance sector.
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the administrative stage of a legal saga that has attracted interest beyond competition law specialists.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023